Abalos Therapeutics
Latest round
- Series A
Last raised
- Sep 2021
Total raised
- $51M
Investors
- 8
About Abalos Therapeutics
Founded in 2019 in Germany, Abalos Therapeutics GmbH specializes in the development of anti-cancer therapies, particularly through its proprietary Adapt Innate technology.Abalos Therapeutics specializes in developing innovative anti-cancer therapies that leverage their proprietary Adapt Innate technology, focusing on harnessing the immunostimulatory properties of arenaviruses. Their lead product candidate, ABX-001, is designed to persist and replicate within cancerous and antigen-presenting cells, enabling a targeted immune response that combats primary tumors and their metastases.Abalos Therapeutics' revenue model is centered on partnerships and collaborations with healthcare institutions and research organizations. Revenue is generated primarily through strategic alliances with pharmaceutical companies interested in bringing ABX-001 and future candidates to market. The company anticipates earning revenue through licensing agreements post-commercialization, incorporating upfront payments, milestone payments linked to clinical and regulatory successes, and royalties from product sales. The company aims to initiate clinical trials for its lead product candidate in 2025, with a strategic focus on penetrating new markets, although specific regions for expansion have not been outlined.
Who invested in Abalos Therapeutics
8 investors across 2 rounds
See all investors in Abalos Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Abalos Therapeutics
Who invested in Abalos Therapeutics?
Abalos Therapeutics has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Abalos Therapeutics raised?
Abalos Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Abalos Therapeutics last raise money?
Abalos Therapeutics's most recent round on record is a Series A, in Sep 2021.
What does Abalos Therapeutics do?
Founded in 2019 in Germany, Abalos Therapeutics GmbH specializes in the development of anti-cancer therapies, particularly through its proprietary Adapt Innate technology.
Where is Abalos Therapeutics headquartered?
Abalos Therapeutics is headquartered in Germany.
Which VCs invest in companies like Abalos Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back pharmaceuticals companies at Abalos Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Abalos Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.